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Background: Alpha-Mannosidosis is a rare lysosomal storage disorder, caused by the deficiency of the enzyme
alpha-Mannosidase. Clinically it is characterized by hearing impairment, skeletal and neurological abnormalities and
mental retardation. In order to characterize the clinical features and disease progression of patients affected by
alpha-Mannosidosis, a survey study was conducted. 43 patients from 4 European countries participated in this
longitudinal study. Age range of the participants was 3 to 42 years. For each patient a medical history, complete
physical and neurological examination, joint range of motion and assessment of physical endurance and of lung
function were completed. In addition, serum and urinary oligosaccharide levels were analysed.
Methods: In this multicenter longitudinal study clinical data of 43 alpha-Mannosidosis patients were collected. In
addition to objective clinical measurements biochemical assays were performed.
Results: Data analysis revealed a wide spectrum of clinical presentation regarding the severity and disease
progression. Most clinical abnormalities were observed in the musculoskeletal and neurological system. All patients
showed mental retardation and hearing loss from early childhood. An impairment in physical endurance was
revealed by the 6-minute walk and 3-minute stair stair climb tests. There was only slight progression of a few
clinical findings: Psychiatric troubles in both groups essentially, and respiratory dysfunction under 18 years. The
serum and urinary oligosaccharide levels were increased in all affected individuals and correlated well with the
6-minute walk and 3-minute stair climb test results.
Conclusions: This study confirms that alpha-Mannosidosis is a very heterogeneous disorder regarding both, disease
severity and progression. As it has been shown that Mannosidosis patients are able to perform lung function tests
and the 6MWT and stair-climb test, these clinical parameters apparently can be used as clinical endpoints for
clinical trials. Oligosaccharide levels appeared correlated with functional testing and may serve as biomarkers of
disease severity, progression and response to treatment.
Trial registration: ClinicalTrials.gov Identifier = NCT00498420 and EuropeanCommission FP VI contract LHSM-CT-2006-
018692.
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Alpha-mannosidosis (OMIM 248500) is a rare lysosomal
storage disorder caused by the deficiency of alpha-
Mannosidase (MAN2B1, EC 3.2.1.24), a lysosomal enzyme
responsible for the degradation of N-linked oligosaccha-
rides. Alpha-mannosidosis is a progressive disorder, and
characteristic features include mental retardation, coarse
facial appearance, hearing loss, skeletal deformities, cen-
tral nervous system involvement and immune defects.
Based on severity two distinct phenotypes of alpha-
Mannosidosis have been described: A severe form (type I)
with hepatomegaly and early death caused by severe infec-
tions [1], and an attenuated (mild) form (type II) with
hearing loss, mental retardation and slow progression with
survival into adulthood [2]. A further classification into a
mild, moderate and severe type of alpha-Mannosidosis
seems to be questionable as the clinical presentation varies
considerably [3]. In this paper the term “severe form”
(type I) and “mild form” (type II) are used.
Type I alpha-Mannosidosis leads to early death, pri-
marily caused by the involvement of the central nervous
system and recurrent infections. In patients affected by
the mild form first symptoms such as hearing loss and
skeletal abnormalities are often seen before the age of 10
years; later ataxia and mental retardation become more
and more evident. In alpha-Mannosidosis broad he-
terogeneity is seen not only in the clinical manifestations,
but also in the spectrum of mutations of the alpha-
Mannosidase gene (MAN2B1) that is located on chromo-
some 19p13.2. Currently, 125 different disease-causing
mutations have been identified [4]. The prevalence of
alpha-Mannosidosis is not exactly known, Meikle et al.
have calculated a prevalence of 1 case in 1 million live
births [5], a similar prevalence was observed in the
Netherlands [6].
There are many reviews extensively describing the
clinical manifestation of the lysosomal storage disorder
alpha-Mannosidosis; a longitudinal study, however, eva-
luating the progression of the disease in a greater num-
ber of patients is lacking. Furthermore, the clinical
reports that have been published so far have been based
on a small number of patients and have not included
quantitative measurements of clinical features. There-
fore, the EU consortium HUE-MAN (Towards the
Development of an Effective Enzyme Replacement Ther-
apy for Human Alpha-Mannosidosis) was established in
order to conduct a survey of the natural history study of
the human disease alpha-Mannosidosis [7]. The purpose
of this study was also to define possible clinical end-
points for future clinical trials. In addition, clinical
phenotypes of selected European patients have been
determined and important medical data such as the
results of clinical and neurological investigations,
ophthalmological and hearing examinations, lung andheart function and measurement of general endurance
using the 6-minute walk test (6MWT) and 3-minute
stair climb test (3MSCT) were collected.
Methods
Clinical evaluation
The aim of this multicenter, multinational prospective
study was to evaluate clinical and surrogate parameters
known to be affected in alpha-Mannosidosis patients.
The design of this observational study was open, non
randomized with several objective clinical measurements,
laboratory measurements and some investigator evaluated
parameters. In addition, some patient assessed measure-
ments (Quality of Life and Health Questionnaires) were
collected. Informed consent was obtained prior to any
study related activity and the subject, or the subject’s legal
guardian, provided consent using the Ethics Committee
(EC)-approved consent form and with compliance to local
and European Union regulations, International Confe-
rence on Harmonization (ICH) and Good Clinical Practice
(GCP) standards.
Only patients with the mild form (type II) were en-
tered into this study if they had a documented deficiency
of serum or leukocyte acid alpha-Mannosidase enzyme
activity level. Patients had to be excluded from the study
if they had received a bone marrow transplantation or
had used an investigational drug within 30 days prior to
study enrollment. Known medical conditions or serious
intercurrent illness that could significantly interfere with
study compliance were further exclusion criteria. In all
subjects, clinical symptoms (with special emphasis on
hearing difficulties and visual impairment) and history of
infections, surgical procedures, hospitalizations and use
of medication were recorded. The physical examination
included vital signs, height and weight, evaluation for
heart murmur, and for liver and spleen size.
As a measure of general endurance the 6-minute walk
test (6MWT) was conducted at baseline and at visit 12
and 24 months [8]. The values are given as LOCF = Last
Observation Carried Forward, that means that for
patients who have missing data, the last previous data
point which was actually recorded is carried forward.
The purpose of this is to get a mean value which is not
influenced by the large fluctuations in the means that
may occur because of the different levels for the
patients. Because there are no published normal values
of the 6MWT covering the full age range, the published
references were combined in order to overcome this
difficulty. For this purpose, a predictive model of the
6MWT outcomes was derived from the models published
by Geiger et al. [9], Gibbons et al. [10] and Enright et al.
[11]. For the late adolescence, an obvious adjustment to
the Geiger model was introduced. In order to join the
three models, linear interpolation was applied where the
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a combined predictive 6MWT model that could be used
across the full age range. Sensitivity analyses confirmed
the suitability of the proposed model.
In the 3-minute stair climb that was conceived on the
basis of a combination of published tests [12,13], patients
were instructed to climb as many steps as possible in a
3-minute period.
Joint range of motion encompassing passive flexion and
extension at the shoulders, elbows, and knees was mea-
sured with a goniometer utilizing standard technique. For
assessment of heart function a standard 12-lead electro-
cardiogram (ECG) was performed. Interpretation of the
ECG included assessment of heart rate, cardiac rhythm,
intervals, axis and conduction defects. Echocardiograms
were optional, interpretation included assessment of the
size of the chambers and pumping function.
Forced vital capacity (FVC), forced expiratory volume
(FEV1) and peak flow were measured in accordance with
American Thoracic Society (ATS) standards [14]. The
range of FVC was expressed as percentage of expected
depending on age, size and sex.
Ophthalmological assessments included slit lamp
examination of the cornea and lens, best corrected visual
acuity (in dp) and examination of the retina of both eyes
at baseline, at 12 month and at 24 months. All three
were evaluated and assessed as Normal or Abnormal
and the abnormal were classified as Non Clinically
Significant or Clinically significant for each eye.
Hearing was tested by pure-tone audiometry for air
and bone conduction in the conventional frequency
range and for air-conduction in the extended high
frequency range.
For assessment of activities of daily living, severity of
pain, and extent of disability the Health Assessment
Questionnaire (HAQ) was used for subjects older than
18 years of age [15]. For subjects ≤ 18 years of age the
Childhood Health Assessment Questionnaire (CHAQ)
was completed by the caregivers [16].
Oligosaccharide analysis
Serum
Serum samples used in this study were stored at −20°C.
Control serum samples were obtained from healthy
volunteers within the department.
250 μL of serum were mixed with 1 μg of a disaccharide
(Man(β1-4)GlcNAc) which served as an internal standard.
The glycans were purified on a C18-Sep-Pak (Waters Ltd)
and on a column of 150 mg of nonporous graphitized
carbon (Alltech, Deerfield, IL, USA). After conditioning,
the C18-Sep-Pak by sequential washing with methanol
(5 mL), and 5% acetic acid (10 mL), the sample was loaded
onto the Sep-Pak and the glycans were eluted with 3 mL
of 5% acetic acid. The glycans were then desalted on acolumn of 150 mg of nonporous graphitized carbon
(Alltech, Deerfield, IL, USA). The column was sequentially
washed with 5 mL methanol and 10 mL 0.1% v/v TFA.
The glycans were applied to the column and washed with
15 mL of 0.1% v/v TFA. The elution of the glycans was
conducted with the application of 5 mL of 25% v/v aceto-
nitrile in water containing 0.1% v/v TFA. The fractions
were freeze-dried.
Glycans were derivatized with 2-aminobenzamide as
previously described, with minor modifications [17]. The
freeze-dried glycans were dissolved in 100 μL of a solu-
tion (freshly prepared by mixing 64 mg of sodium
cyanoborohydride, 41 mg of 2-aminobenzamide, 700 μl
of dimethylsulfoxide, and 300 μl of acetic acid). The
reaction mixture was stirred for 2 h at 80°C. To remove
the excess of reagents, 500 μL of 75 and 85% methanol
was added in succession to the reaction mixture and
evaporated. After addition of 2 mL of water, the pH of
the solution was adjusted to 10 with diluted ammonia
solution and the excess of reagents was extracted with
500 μL of chloroform (five times). The aqueous phase
was neutralized with dilute acetic acid prior to lyophi-
lization. Finally, the derivatized glycans were further
purified on a Sep-Pak C18 (Waters, Saint-Quentin en
Yvelines, France). The Sep-Pak C18 was conditioned with
methanol (5 mL) and water (10 mL). The derivatized gly-
cans dissolved in water were applied on the cartridge,
washed with 15 mL of water and eluted with 3 mL of 25%
acetonitrile in water. Acetonitrile was evaporated under a
stream of nitrogen and the 2-aminobenzamide derivatized
glycans were freeze-dried.
The 2-aminobenzamide labeled glycans were loaded on a
Shodex Asahipak NH2P-50 column (5 μm; 4.6 × 250 mm;
VWR). The mobile phases were acetonitrile (solvent A)
and water (solvent B). The column was equilibrated with
85% A. After injection, isocratic conditions were applied
for 15 min with 85% A, followed by a gradient with the
following conditions: (step 1) 85-80% A for 15 min, linear
gradient; (step 2) 80-50% A for 60 min, linear gradient;
(step 3) 50% A for 20 min. The flow rate was 0.7 mL/min.
2-aminobenzamide derivatized glycans were detected on a
Dionex RF 2000 fluorescence detector at an excitation of
350 nm and an emission wavelength of 450 nm.
Urine
Samples used in this study were stored at - 20°C. Control
urine samples were obtained from healthy volunteers
within the department.
Urine (0.207 μmol creatinine equivalents) was mixed
with 2.608 nmol of a disaccharide (Man(β1-4)GlcNAc)
which served as an internal standard and freeze-dried.
Glycans were derivatized with the 2-aminobenzamide as
previously described, with minor modifications [17]. The
freeze-dried glycans were dissolved in 100 μL of a solution
Beck et al. Orphanet Journal of Rare Diseases 2013, 8:88 Page 4 of 13
http://www.ojrd.com/content/8/1/88(freshly prepared by mixing 64 mg of sodium cyanobo-
rohydride, 41 mg of 2-aminobenzamide, 700 μl of dime-
thylsulfoxide, and 300 μl of acetic acid). The reaction
mixture was stirred for 2 h at 80°C. To remove the excess
of reagents, 500 μL of 75 and 85% methanol was added in
succession to the reaction mixture and evaporated. After
addition of 2 mL of water, the pH of the solution was
adjusted to 10 with diluted ammonia solution and the
excess of reagents was extracted with 500 μL of chloro-
form (five times). The aqueous phase was neutralized with
dilute acetic acid prior to lyophilization. Finally, the
derivatized glycans were further purified on a Sep-Pak C18
(Waters, Saint-Quentin en Yvelines, France). The Sep-Pak
C18 was conditioned with methanol (5 mL) and water
(10 mL). The derivatized glycans dissolved in water were
applied on the cartridge, washed with 15 mL of water and
eluted with 3 mL of 25% acetonitrile in water. Acetonitrile
was evaporated under a stream of nitrogen and the 2-
aminobenzamide derivatized glycans were freeze-dried.
The 2-aminobenzamide labeled glycans were loaded
on a Shodex Asahipak NH2P-50 column (5 μm; 4.6 ×
250 mm; VWR). The mobile phases were acetonitrile
(solvent A) and water (solvent B). The column was
equilibrated with 85% A. After injection, isocratic condi-
tions were applied for 15 min with 85% A, followed by a
gradient with the following conditions: (step 1) 85-80%
A for 15 min, linear gradient; (step 2) 80-50% A for
60 min, linear gradient; (step 3) 50% A for 20 min. The
flow rate was 0.7 mL/min. 2-aminobenzamide deriva-
tized glycans were detected on a Dionex RF 2000 fluo-
rescence detector at an excitation of 350 nm and an
emission wavelength of 450 nm. The mass of these gly-
cans were determined using MALDI-TOF-MS.
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry
MALDI-MS experiments were carried out on Voyager
Elite DE-STR Pro instrument (PersSeptive Biosystem,Figure 1 Height of males with Alpha-Mannosidosis. Outer lines indicateFramingham, MA) equipped with a pulsed nitrogen laser
(337 nm) and a gridless delayed extraction ion source. The
spectrometer was operated in positive reflectron mode by
delayed extraction with an accelerating voltage of 20 kV
and a pulse delay time of 200 nsec and a grid voltage of
66%. All spectra shown represent accumulated spectra
obtained by 400–500 laser shots. Sample was prepared by
mixing a 1 μL aliquot (5–10 pmoles) with 1 μL of matrix
solution on the MALDI sample plate. The matrix solution
was prepared by saturating methanol–water (1:1) with 2,5
dihydroxybenzoic acid (DHB) (10 mg/mL).
Results
Demographics and body measurements
Fourty five patients from 4 centers (Children’s Hospital,
University of Mainz, Germany; Department of Medicine,
University Hospital of Tromsoe, Norway; Dept. of Genetic
Medicine, St. Mary’s Hospital, Manchester UK; and the
Department of Pediatrics, Charles University, Prague,
Czech Republic) could be screened for this study; 31 were
males and 14 were females. The age range was 1.4 – 42.1
years, mean age was 19.8 years. 22 were under the age of
18 years and 23 patients 18 years or older at the time of
enrolment. 43 patients completed the 2 years, two chil-
dren discontinued because of non-compliance.
Figures 1 and 2 show the absolute height of males and
females at baseline, compared to published growth curves
for normal individuals from Northern European countries
[18]. Only 4 children (3 boys and 1 girl) had an height
below the curve of the double standard deviation. Mean
height of the adult patients was 162 ± 9 cm SD with a
broad range from 145 to 179 cm.
There is a natural increase in height of patients in the
age group < 18 years as the majority of patients are in a
growth period (Figure 3).
Most of the patients in the younger age have an overall
normal BMI, there are two girls, 16 and 17 years old,
who are overweight (BMI = 28.2 and 25.4, respectively).- 2 SD and + 2 SD.
Figure 2 Height of females with alpha-mannosidosis. Outer lines indicate - 2 SD and + 2 SD.
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are overweight with a BMI greater than 24.0; furthermore,
in this group there are two females (age 27 and 32) who
show severe obesity with a BMI of 39 and 33, respectively.Clinical assessments
All patients had a physical examination performed at
baseline, 12 months and at 24 months. Due to an unex-
pected early termination of the study several patients
could not complete visit 3 after 24 months.
In the general examination, all patients (children and
adults) had any abnormal clinical findings such as coarse
facial features (13 of 43), ear infections (8 of 43), heart
murmur (9 of 43) and skeletal deformities such as ky-
phoscoliosis and pectus carinatum.Figure 3 Change of height of children and adults over time.Data from the ophthalmological investigations showed
that 2 patients (age 14 and 22 years) had corneal
clouding, 2 patients (age 39 and 30 years) had a cataract
and 2 patients (age 15 and 34 years) were almost blind
(vision = 6/95 at the better-seeing eye) due to retinal
pigmentary degeneration. In one patient (25 years) a pale
papilla was seen.
From Table 1 it can be seen that the baseline visual
acuity is approximately the same for both age groups.
Over the observation period, there is only a insignificant
deterioration in visual acuity.
All patients who were able to cooperate had an assess-
ment of their hearing performed at baseline, at 12 months
and at 24 months. The assessment included: Bone con-
duction, air conduction (conventional frequency) and air
conduction (high frequency). All patients over the age of 3
Table 1 Visual acuity (best corrected, best seeing eye) of
both age groups
Normal vision
(6/6 - ≥ 6/12)
Low vision
(≤ 6/12 - ≥ 6/120)
Age Group N N
Age < 18 Years (N = 20) 18 2
Age ≥ 18 Years (N = 23) 20 3
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ring aids. Data of the hearing tests, expressed as decibel,
show that baseline values are quite similar between the
two age groups (Figures 4, 5, 6).
The data also seem to indicate a minor change of
hearing loss over the first part of the observation period
which also is similar between the groups. For the second
part of the observation period from 12 to 24 months there
seems to be a slight improvement in hearing. Missing data
limits a more detailed interpretation of the results.
For the cardiovascular system 24% of the patients
under the age 18 years and 17% of patients age 18 or
over presented abnormal findings. In the majority of
cases they were clinically not significant as exemplified
as “murmur” on cardiac auscultation. Five patients had
an abnormal echocardiogram: The findings were given
as valvular insufficiency or decreased ventricular ejection
fraction. Two patients (one in each age group) had an
abnormal ECG that was assessed as clinically significant;
more findings were not reported.
The musculoskeletal area showed typical abnormal
findings for this disease such as macrocephaly, contrac-
tures, scoliosis, genua valga, hip dysplasia and deformities
of feet. In the younger age group (patients < 18 years) 62%
of the patients had abnormal findings for this body area. ItFigure 4 Hearing testing - bone conduction (dB HL). Mean ± SE (= 1 Sseems to be stable over the observation period, which
would also be expected. In the older patients pathological
signs and symptoms of the musculoskeletal system were
observed at an even higher rate than in the younger age
group: In this population 92% of the patients had abnor-
mal findings for this body area at baseline. After two years
94% of adult patients had abnormal findings.
Neurologically 71% of the 20 patients under the age of
18 years showed abnormal signs and symptoms at
baseline, whereby the main clinical sign was ataxia that
was seen in 12 of the patients. Further findings included
dysarthria, dysmetria, and mental retardation. A similar
rate of pathological neurological findings (79%) was seen
in the older patients. Over the observation period this
did not change significantly, in either the younger or
older age group.
Psychologically, 52% of the patients had abnormal find-
ings at baseline. Despite a decrease at visit 2 in the per-
centage of patients with abnormal findings (e.g. psychotic
disorder) there was a significant increase at visit 3 with
79% of the patients showing abnormal findings.
6-minute walk test and 3-minute stair climb test
All patients were expected to perform a 6-minute walk
test (6MWT) at baseline, at 12 months and at 24
months. However, as the youngest patient was not
cooperating, only 19 of 20 patients under the age of 18
carried out the test at baseline. Following amendment 1
some patients did not have the opportunity to complete
either the amended 18 months test (due to the timing of
the amendment) or the 24 months test (because of the
early stop of the study). Hence the number of patients
completing the projected tests differ considerably
between time points.tandard deviation).
Figure 5 Hearing testing - air conduction: conventional frequency range (dB HL) mean ± SE (= 1 Standard deviation).
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within 6 minutes at baseline ranged from 60,0 to 470,0 m
with a mean value of 341,1m (SD = 104,9 m) in the youn-
ger age group, and from 69,0 m to 521,3 m with a mean
value of 324,7 m (SD = 118,1 m) in the older group.
In order to compare the outcome of the 6MWT in the
patient group with normal subjects, the predictive model
of the 6MWT outcomes, published by Geiger et al. [9],
Gibbons et al. [10] and Enright et al. [11], was used (see
Methods). Calculations by using the Geiger model show
that for the patients in the younger patient population
the functional capacity is reduced to a value between 50
and 60% of the values for normal patients of the sameFigure 6 Hearing testing air conduction: high frequency range (dB HLage (Figure 7). For the older age group (above 18 years
of age) the functional capacity for a 6 MWT is further
reduced to less than 50% of the functional capacity for
normal patients (ie 40 – 45%).
At baseline, the number of stairs that could be climbed
was 92–166 stairs with a mean value of 141 (SD = 30)
stairs in the younger age group, after 1 year a slight
improvement was observed (106–197 stairs, mean value
160, SD = 39 stairs). Patients at the age over 18 years
could climb at baseline 22–186 stairs (mean value = 100,
SD = 58), they also showed an improvement after one
year (43–197 stairs, mean value = 126, SD = 55 stairs).
Data of the 2 years visit are not available.) Mean ± SE (= 1 Standard deviation).
Table 2 Results of the 6-min walk test
N Mean Std. Min Max
Age 0 - < 18 years
Distance (m)
Baseline 19 341.1 104.9 60.0 470.0
12 Months 19 340.0 106.3 182.3 540.0
18 Months 10 331.6 128.9 94.0 478.0
24 Months 13 393.2 142.3 164.0 770.0
Age ≥ 18 years
Distance (m)
Baseline 23 324.7 118.1 69.0 521.3
12 Months 19 325.4 139.2 64.0 573.0
18 Months 6 450.5 134.2 254.0 630.0
24 Months 15 305.8 89.2 105.0 430.0
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Eleven of patients under the age of 18 years and 9 adult
patients were able to perform a pulmonary function test
at baseline, at 12 months, at 18 months and at 24 months.
The assessments included: Forced vital capacity (and
percentage of predicted value, depending on age, size and
sex = % predicted FVC), forced expiratory volume during
first second (and percentage of predicted value = %
predicted FEV1) and peak expiratory flow rate. In all
measurements there was a significant range, spanning
from about 30% to 90% of predicted FVC and FEV1. No
patient was dependent on night time ventilation.
In patients under the age of 18 the % predicted FVC is
decreasing from a baseline value of 71% to 61% at visit 3
(Figure 8) that clinically is not significant.
For % predicted FEV1 the data also show no signifi-
cant change within 24 months (Figure 9). In the olderFigure 7 6-minute walk test: percentage of normal ± SE.age group the pulmonary function capacity is similar at
baseline and after the 2 years period.
For the older age group the overall picture of the
pulmonary function capacity is similar over time; for the
younger age group the data seem to indicate that over
the observation period there is up to a 10% decrease in
pulmonary function, that clinically is not significant.
Cardiology assessment
All patients had an assessment of their ECG and an
overall interpretation of an echocardiogram at baseline,
at 12 months and at 24 months. The ECG and echo-
cardiogram were evaluated and assessed as Normal or
Abnormal and the abnormal results were further classi-
fied as Non Clinically Significant or Clinically significant.
There are two patients in the older age group and one in
the younger age group who present with clinically
significant abnormal findings. The findings are given as
valvular insufficiency or stenosis or decreased ventricular
ejection fraction. These abnormal findings do not change
over the observation period.
Oligosaccharides in serum and urine
Valid serum oligosaccharide levels were available for 5
subjects under the age of 18 years and from 11 individuals
over 18 years. The older patients had higher concentra-
tions (11.05 – 82,45 nmol/ml, mean = 21,49 nmol/ml)
than the younger patients (7.16 – 33.49 nmol/ml, mean =
16.33 nmol/ml). In the urine, the oligosaccharide concen-
tration was similar in both age groups, whereby the mean
value at the age under 18 years (n = 10) was 323.00 nmol/
ml and in adults (n = 15) 280.62 nmol/ml. The 6MWT as
an indicator of general endurance was examined as a func-
tion of oligosaccharide urine/serum. And as can be seen
Figure 8 Lung function: range of FVC, expressed as percentage of expected depending on age, size and sex.
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long walking distance and vice versa. Similar results were
obtained when the analysis was applied to the 3 minute
stair climb test (Figure 11).The health assessment questionnaires
The health assessment questionnaires confirm that the pa-
tients are dependent to a high degree upon third party as-
sistance. This is not age dependent as it is seen in both
age groups. A major difference is the pain score: The VAS
scores clearly show that the older age group seem to have
more pain than the younger age group (as far as the men-
tally retarded children could give faithful responses). TheFigure 9 Lung function: percentage of predicted forced expiratory voreason for this is not clear, but it is likely to represent pro-
gressive bone and joint disease.
Discussion
In the present study that was aimed to establish the range
and diversity of clinical features of alpha-Mannosidosis
and to define clinical endpoints for future clinical trials,
information was collected for 43 affected subjects over the
age of 3 years, identified by four centers from four
European countries. A total of 45 patients were screened;
during the course of the study, however, two patients
discontinued because of no-complicance. In addition to
clinical investigations, analyses of oligosaccharide concen-
tration in urine and serum and were performed.lume during first second.
Figure 10 6 minutes walk test (% of predicted) versus oligosaccharide level in urine by age group. Correlation Factor = 0,61602,
P-Value = 0,0014).
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assess the natural history of patients diagnosed with alpha-
Mannosidosis and to evaluate short term (24 months)
changes in disease parameters. Previously only a few
retrospective studies describing the clinical course have
been published and these have included only a small num-
ber of patients: Yunis et al. analyzed the clinical course of
five patients who in their age ranged from 15 to 24 years
[19]. The authors pointed out that the first signs and
symptoms such as hearing problems, skeletal changes and
facial coarsening could be seen from the age of five years;Figure 11 Minutes stair climb test versus oligosaccharide level in urinthe degree of clinical expression, however, varied from
patient to patient, even among siblings. In the brother and
sister, described by Ara et al., at the age of 27 and 29 years,
respectively, neurological changes such as cerebellar
syndrome, hearing loss and mental retardation were the
leading clinical signs; except in the sisters’s speech
capacity, over a period time of 25 years no progression
was observed [20]. Neurodevelopmental assessments
including general intelligence, language, visual spatial
skills and overall adaptive abilities were performed in
three brothers with alpha-Mannosidosis; follow-up studiese by age group. Correlation Factor = 0,56805, P-Value = 0,0072).
Beck et al. Orphanet Journal of Rare Diseases 2013, 8:88 Page 11 of 13
http://www.ojrd.com/content/8/1/88did not show signs of progressive deterioration of cogni-
tive deficits, except receptive language capability [21].
The data from the physical examination confirm that
alpha-Mannosidosis is a complex disorder affecting
many organs such as the eyes, ears and the central
nervous and the musculoskeletal system. Abnormalities
of the musculoskeletal system are one of the clinical
findings that affect almost all patients. Whereas in
patients under the age of 18 years skeletal deformities
were seen in 62%, scoliosis, genua valga, hip dysplasia
and joint contractures have been observed in almost all
adult patients (92%). A similar frequency of skeletal
changes (55 of 59 patients) was described in the review
of Chester et al. [22]. A lessening of the bone abnor-
malities, as described by Yunis et al. [19] could not be
confirmed in our study; the severity of of bone deformities
did not change over the time. In contrast to the observa-
tions of Autio et al. [23] and Yunis et al. [19] a noteworthy
growth retardation was not seen in all patients in spite of
significant skeletal abnormalities: Only four children had
an height below the normal range, in the adults a broad
range of height from 145–179 cm was seen. Only a few
patients have a BMI above the normal range.
The joint range was measured rigorously, but in a non
functional manner, and despite many abnormal findings
in the physical examination for the joints, there seemed
to be no deterioration in range of joint movement over
the observation period.
Ataxia and mental retardation were the prominent
neurological findings observed in this study; a progres-
sion of these symptoms within 2 years could not be seen.
A similar observation was made by Autio et al. who
described a merely slow progression of mental retardation
in eight patients. These patients had an IQ of 60–80,
whereby they scored better in nonverbal tests which can
be explained by the speech disturbance due to the hearing
impairment [23].
Hearing loss (bone and conductive) is seen in all
patients affected by an alpha-Mannosidosis [22,24]. The
impaired hearing is predominantly due to sensorineural
damage, but because it may result also from early ear
infections it represents a mixture of conductive and
neurosensory components as it has been seen in this
study. As hearing loss appears during early childhood, it
is not surprising that in our study both age groups show
more or less the same degree of hearing impairment. A
significant deterioration within the observational time
could not be seen.
Ophthalmological investigations in most patients
revealed only minor abnormalities such as slight corneal
opacities or cataract and amblyopia. These results are in
accordance with the observations of other authors who
also have described strabismus, hypermetropia and slight
corneal clouding in only a few cases [23,25]. Retinalpigmentary degeneration, leading almost to blinding, has
been found in two of our patients; a similar observation
was made by Springer et al. in two brothers [26]. In
general, however, retinal dystrophy seems to be rare in
Mannosidosis patients. There were no significant changes
of the ophthalmological findings in our study throughout
the observation period.
Besides innocent heart murmur the majority did not
have significant cardiac abnormalities. In five patients,
however, valvular insufficiency or decreased ventricular
ejection fraction was seen by echocardiogram. Two
patients had an abnormal ECG that was not specified in
detail by the investigator.
Because to our knowledge there is a paucity of data on
respiratory function in Mannosidosis patients, lung func-
tion tests were performed in the present study. However,
not all patients were able to perform the lung function
tests because of their mental status. In the younger age
group there was a decline of percentage predicted FVC
within the observation time of 2 years. The older
patients had a lower percentage predicted FVC (61%) at
baseline in comparison with the children (Figure 8).
The 6 MWT has not previously been performed in
Mannosidosis patients, therefore this method was used
to measure the general endurance of these individuals in
the present study. However, both the actual distance
measured as well as the percentage of normal distance
does not show any consistent picture either in the younger
or in the older patient age group. Both groups show a
significant range, spanning from about 60 to about 500
meters. A number of factors such as parental influence,
growth or a training effect may have influenced the
6MWT. A similar consideration applies to the 3 minute
stair climb test. There is no clear trend throughout the
observation period for either age group probably for
similar reasons as stated for the 6 MWT.
Mannosidosis patients excrete high amounts of
undegraded oligosacharides that can be detected in their
urine. Serum samples showed similar findings. The
storage material is composed mainly of tri-, tetra-, and
pentasaccharides and probably represents the products
of endo-ß-N-acetylglucosaminidase digestion of the
sugar chains of high mannose type glycoproteins [27,28].
In our study, an interesting correlation of the 6MWT
and oligosaccharide excretion could be observed in both
age groups: Patients with a high oligosaccharide excre-
tion have an impaired ability to walk (Figure 10). The
same correlation was found of oligosaccharide excretion
and the stair climb test (Figure 11). As a relationship of
general endurance and urinary oligosaccharide levels
was seen in all age groups, it can be presumed that the
oligosaccharide excretion rather depends from the seve-
rity of the disease than from the age of the patients. In
patients affected by mucopolysaccharidosis type VI a
Beck et al. Orphanet Journal of Rare Diseases 2013, 8:88 Page 12 of 13
http://www.ojrd.com/content/8/1/88similar observation was made: MPS VI patients who had
low height values excreted higher amounts of glycos-
aminoglycans than those who had normal or almost
normal height values [29]. From these findings it can be
concluded that urinary oligosaccharide excretion can be
used as a surrogate marker in clinical trials for example
for the development of therapeutic principles such as
enzyme replacement therapy.
Conclusions
The variable clinical presentation of the Mannosidosis
patients investigated in this survey confirms that alpha-
Mannosidosis is a highly heterogeneous disorder, as it has
already been described by several authors [1,3,22]. It could
be demonstrated that there was only slight progression of
a few clinical findings within the observational time: In
both groups psychiatric troubles, and impaired lung func-
tion in patients under the age of 18 years. Our study has
revealed that in both age groups significant neurological
abnormalities such as ataxia and dysarthria can be ob-
served. And in a mouse model for alpha-Mannosidosis it
could be demonstrated that the intravenous administra-
tion of recombinant alpha-Mannosidase resulted in an
improvement of the neuromotor disabilities found in
untreated mice [30]. From these results it can be consi-
dered to incorporate not only the lung function and
6MWT or 3stair climb test, but also neurological investi-
gations as clinical parameters for therapeutic clinical trials
[31]. As additional biomarkers oligosaccharide levels in
serum and/or urine may serve.
Abbreviations
MALDI-TOF: Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry; BMI: Body Mass Index; dB HL: Decibel/hearing level; VAS: Visual
Analogue Scale; SD (or SE): Standard deviation.
Competing interests
The study is funded by the EU in the “HUE-MAN” consortium through a
Framework 6 grant of 3.2 million Euro for a period of 36 months. The entire
grant covers both scientific programs and clinical programs. The authors;
except Jens Fogh, who is employed at the Danish company Zymenex;
confirms independence from any sponsors; the content of the article has not
been influenced by any sponsors.
Authors’ contributions
DM has designed the study and has evaluated patients. PS and JF are the
coordinators of the project. MB, JZ and JEW have performed the clinical
evaluations of the patients. JCM has performed the biochemical analyses.
KJO has carried out the statistical analysis. All authors contributed to the
concept of the study and participated in drafting the manuscript and
approved the final manuscript.
Acknowledgements
This work was supported by the HUE-MAN consortium (European
Commission FP VI contract LHSM-CT-2006-018692). It is written in memory of
Dr. Ed Wraith who deceased during the preparation of the manuscript. Dr.
Ed Wraith made significant contributions to research and improvements in
the care of patients affected by a lysosomal storage disorder. He will be
fondly remembered by colleagues for his enormous scientific work and his
kindness, and by patients for his excellent clinical skills and compassion.Author details
1Center for Pediatric and Adolescent Medicine, University Medical Center,
Langenbeckstraße 1, 55131 Mainz, Germany. 2Larix ApS, Tempovej 44,1, 2750
Ballerup, Denmark. 3Manchester Academic Health Science Centre, Central
Manchester University Hospitals NHS Foundation Trust, St Mary’s Hospital,
Oxford Road, Manchester, M13 9WL, United Kingdom. 4Department of
Pediatrics, First Faculty of Medicine, Charles University, Ke Karlovu 2, Prague 2
120 00 Czech Republic. 5Unite’ Mixte de Recherche CNRS/USTL 8576-UGSF,
Unité de Glycobiologie Structurale et Fonctionnelle, IFR 147, Bat C9,
Université des Sciences et Technologies de Lille, 59655 Villeneuve d’Ascq
Cedex, France. 6Department of Biochemistry, Christian-Albrechts-Universität
Kiel, Olshausenstr. 40, 24098 Kiel, Germany. 7Zymenex A/S, Roskildevej 12 C,
3400 Hillerød, Denmark. 8The Tromsø Centre of Internal Medicine (TIS as),
House of Health, Sjøgata 31/33, NO9008 Tromsø, Norway.
Received: 3 February 2013 Accepted: 13 June 2013
Published: 20 June 2013References
1. Desnick RJ, Sharp HL, Grabowski GA, Brunning RD, Quie PG, Sung JH, Gorlin RJ,
Ikonne JU: Mannosidosis: clinical, morphologic, immunologic, and
biochemical studies. Pediatr Res 1976, 10:985–996.
2. Bach G, Kohn G, Lasch EE, El Massri M, Ornoy A, Sekeles E, Legum C, Cohen MM:
A new variant of mannosidosis with increased residual enzymatic activity
and mild clinical manifestation. Pediatr Res 1978, 12:1010–1015.
3. Malm D, Nilssen O: Alpha-mannosidosis. Orphanet J Rare Dis 2008, 3:21.
4. Riise Stensland HM, Klenow HB, Nguyen LV, Hansen GM, Malm D, Nilssen O:
Identification of 83 novel alpha-mannosidosis-associated sequence
variants: functional analysis of MAN2B1 missense mutations. Hum Mutat
2012, 33:511–520.
5. Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal
storage disorders. JAMA 1999, 281:249–254.
6. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S,
Niezen-Koning KE, van Diggelen OP: The frequency of lysosomal storage
diseases in The Netherlands. Hum Genet 1999, 105:151–156.
7. The HUE-MAN Project: Towards the development of an effective enzyme
replacement therapy for human alpha-mannosidosis. [http://www.uni-kiel.
de/Biochemie/hue-man/].
8. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit
Care Med 2002, 166:111–117.
9. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, Geiger H,
Loeckinger A, Stein JI: Six-minute walk test in children and adolescents.
J Pediatr 2007, 150:395–399. 399 e391-392.
10. Gibbons WJ, Fruchter N, Sloan S, Levy RD: Reference values for a multiple
repetition 6-minute walk test in healthy adults older than 20 years.
J Cardiopulm Rehabil 2001, 21:87–93.
11. Enright PL, Sherrill DL: Reference equations for the six-minute walk in
healthy adults. Am J Respir Crit Care Med 1998, 158:1384–1387.
12. Balfour-Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R: A step in
the right direction: assessing exercise tolerance in cystic fibrosis.
Pediatr Pulmonol 1998, 25:278–284.
13. Bolton JW, Weiman DS, Haynes JL, Hornung CA, Olsen GN, Almond CH:
Stair climbing as an indicator of pulmonary function. Chest 1987,
92:783–788.
14. Statement ATS: Standardization of spirometry, 1994, Update 1995. Am J
Respir Crit Care Med 1995, 152:1107–1136.
15. Ramey DR, Raynauld JP, Fries JF: The health assessment questionnaire
1992: status and review. Arthritis care and research: the official journal of the
Arthritis Health Professions Association 1992, 5:119–129.
16. Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status
in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994,
37:1761–1769.
17. Morelle W, Page A, Michalski JC: Electrospray ionization ion trap mass
spectrometry for structural characterization of oligosaccharides
derivatized with 2-aminobenzamide. Rapid communications in mass
spectrometry : RCM 2005, 19:1145–1158.
18. Bonthuis M, van Stralen KJ, Verrina E, Edefonti A, Molchanova EA, Hokken-Koelega
AC, Schaefer F, Jager KJ: Use of national and international growth charts for
studying height in European children: development of up-to-date European
height-for-age charts. PLoS One 2012, 7:e42506.
Beck et al. Orphanet Journal of Rare Diseases 2013, 8:88 Page 13 of 13
http://www.ojrd.com/content/8/1/8819. Yunis JJ, Lewandowski RC Jr, Sanfilippo SJ, Tsai MY, Foni I, Bruhl HH: Clinical
manifestations of mannosidosis - a longitudinal study. Am J Med 1976,
61:841–848.
20. Ara JR, Mayayo E, Marzo ME, Guelbenzu S, Chabás A, Pina MA, Calderón C:
Neurological impairment in α-mannosidosis: a longitudinal clinical and
MRI study of a brother and sister. Childs Nerv Syst 1999, 15:369–371.
21. Noll RB, Netzloff ML, Kulkarni R: Long-term follow-up of biochemical and
cognitive functioning in patients with mannosidosis. Arch Neurol 1989,
46:507–509.
22. Chester MA, Lundblad A, Ockerman PA, Autio S: Mannosidosis. In Genetic
Errors of Glycoprotein Metabolism. Edited by Durand P, O’Brien JF. Milan: Edi-
Ermes; 1982:89–122.
23. Autio S, Louhimo T, Helenius M: The clinical course of mannosidosis.
Ann Clin Res 1982, 14:93–97.
24. Ahmmed AU, O’Halloran SM, Roland NJ, Starkey M, Wraith JE: Hearing loss
due to mannosidosis and otitis media with effusion. A case report and
review of audiological assessments in children with otitis media with
effusion. J Laryngol Otol 2003, 117:307–309.
25. Arbisser AI, Murphree AL, Garcia CA, Howell RR: Ocular findings in
mannosidosis. Am J Ophthalmol 1976, 82:465–471.
26. Springer C, Gutschalk A, Meinck HM, Rohrschneider K: Late-onset retinal
dystrophy in alpha-mannosidosis. Graefes Arch Clin Exp Ophthalmol 2005,
243:1277–1279.
27. Matsuura F, Nunez HA, Grabowski GA, Sweeley CC: Structural studies of
urinary oligosaccharides from patients with mannosidosis. Arch Biochem
Biophys 1981, 207:337–352.
28. Hubbard SC, Robbins PW: Synthesis and processing of protein-linked
oligosaccharides in vivo. J Biol Chem 1979, 254:4568–4576.
29. Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE,
Roberts J, Ketteridge D, Hopwood JJ, et al: Threshold effect of urinary
glycosaminoglycans and the walk test as indicators of disease
progression in a survey of subjects with Mucopolysaccharidosis VI
(Maroteaux-Lamy syndrome). Am J Med Genet A 2005, 134A:144–150.
30. Blanz J, Stroobants S, Lullmann-Rauch R, Morelle W, Ludemann M, D’Hooge
R, Reuterwall H, Michalski JC, Fogh J, Andersson C, Saftig P: Reversal of
peripheral and central neural storage and ataxia after recombinant
enzyme replacement therapy in alpha-mannosidosis mice. Hum Mol
Genet 2008, 17:3437–3445.
31. Damme M, Stroobants S, Walkley SU, Lullmann-Rauch R, D’Hooge R, Fogh J,
Saftig P, Lubke T, Blanz J: Cerebellar alterations and gait defects as
therapeutic outcome measures for enzyme replacement therapy in
alpha-mannosidosis. J Neuropathol Exp Neurol 2011, 70:83–94.
doi:10.1186/1750-1172-8-88
Cite this article as: Beck et al.: Natural history of alpha mannosidosis a
longitudinal study. Orphanet Journal of Rare Diseases 2013 8:88.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
